Skip directly to content

WEBINAR: Cutting Costs by Including Cheaper ARVs on the New York State Medicaid Preferred Drug List for treatment, PEP, and potentially PrEP

January 7, 2019 – Please join Treatment Action Group and Housing Works on January 17th from 10am to 11:15am EST for a free webinar discussing current advocacy to cut costs by scaling up the use of Mylan’s Cimduo (TDF/3TC) and Symfi (EFV/TDF/3TC) as part of New York State Medicaid. Following the webinar, TAG and Housing Works will be seeking sign ons from New York State organizations for a letter requesting that Cimduo and Symfi be included on the preferred drug list (PDL) for treatment, that Cimduo be included for PEP, and that Cimduo be considered for inclusion as PrEP.

REGISTER HERE

Tim Horn from NASTAD will walk webinar participants through the recent FDA approval of Cimduo, Symfi, and Symfi Lo and the advantages of increasing their usage by Medicaid beneficiaries without compromising safety or efficacy for many people living with HIV.

Ionnis Hodges-Mameletzis from the World Health Organization will also walk webinar participants through the suitability of Cimduo (TDF/3TC) for PrEP based upon his extensive work on the topic at WHO.

Jeremiah Johnson from TAG will moderate the discussion.

We hope you can engage in this discussion on January 17th, and if you have any questions ahead of time please email Jeremiah at Jeremiah.Johnson@treatmentactiongroup.org.